Drug-maker Glenmark has formalised an outlicensing deal with Sanofi-aventis to further develop and commercialise the former's novel agents to treat chronic pain, including prospective pain molecule GRC 15300.
The deal breaks a drought of close to two-and-a-half years on the outlicensing front, besides marking a turnaround on the research front for the company. Glenmark will receive an upfront payment of $ 20 million from the Sanofi deal, with milestone and 'double-digit' royalty payments as the molecule is further developed and hits the market. The total value of these payments is pegged at $325 million.
The deal outlines exclusive marketing rights for Sanofi in North America, European Union and
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1786.85 |
Dr. Reddys Lab | 1173.55 |
Cipla | 1525.50 |
Lupin | 2018.35 |
Zydus Lifesciences | 859.10 |
View more.. |